ShareValue scores for DRMA: Valuation 52, Quality 49, Growth 45, Health 55.
DRMANASDAQ
Dermata Therapeutics Inc
$1.11
(-5.13%)
DRMANASDAQ
Dermata Therapeutics Inc
$1.11(-5.13%)
Loading chart...
Sentiment
Verdicts
Value:Fair Value
Quality:Moderate
Growth:Moderate
Health:Moderate
Verdicts
Fundamental Rating
Value Trap Risk
Expected Return
6% to 16%
Rating
Trap Risk
Return
6% to 16%
Valuation
52
Fair Value
Price vs Value
Quality
49
Moderate
Business Strength
Growth
45
Moderate
Revenue & Earnings
Health
55
Moderate
Financial Stability
Momentum
45
Neutral
Price Trend
Company Details
About
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Market Cap$4M
P/E RatioN/A
Dividend YieldNone
Sector Rank#1493
Score Analysis
AI Investment Thesis
Data as of:Aug 7, 2026
|Last calculated:Aug 7, 2026